Synonyms: AMG 510 | AMG-510 | AMG510 | compound (R)-38 [PMID: 31820981] | Lumakras® | Lumykras®
sotorasib is an approved drug (FDA (2021), EMA (2022))
Compound class:
Synthetic organic
Comment: Sotorasib (AMG510) is a covalent KRASG12C inhibitor [2] that was developed by Amgen for anti-tumour potential in KRASG12C-driven cancers. It was the first KRAS-targeting drug to be approved for clinical use.
|
|
Classification ![]() |
|
Compound class | Synthetic organic |
Approved drug? | Yes (FDA (2021), EMA (2022)) |
Approved drug? | Yes. FDA (2021) | EMA (2022) |
IUPAC Name ![]() |
6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one |
International Nonproprietary Names ![]() |
|
INN number | INN |
11370 | sotorasib |
Synonyms ![]() |
AMG 510 | AMG-510 | AMG510 | compound (R)-38 [PMID: 31820981] | Lumakras® | Lumykras® |
Database Links ![]() |
|
CAS Registry No. | 2252403-56-6 (source: PubChem) |
GtoPdb PubChem SID | 404859125 |
PubChem CID | 137278711 |
Search Google for chemical match using the InChIKey | NXQKSXLFSAEQCZ-SFHVURJKSA-N |
Search Google for chemicals with the same backbone | NXQKSXLFSAEQCZ |
Search PubMed clinical trials | sotorasib |
Search PubMed titles | sotorasib |
Search PubMed titles/abstracts | sotorasib |
UniChem Compound Search for chemical match using the InChIKey | NXQKSXLFSAEQCZ-SFHVURJKSA-N |
UniChem Connectivity Search for chemical match using the InChIKey | NXQKSXLFSAEQCZ-SFHVURJKSA-N |